Is Anamorelin available in the country?

Anamorelin (Anamorelin) is a new oral growth hormone-releasing peptide (ghrelin receptor agonist), mainly used to improve appetite and weight management in patients with cancer-related cachexia and weight loss. However, anamorelin has not yet been approved for marketing in China, so domestic patients cannot purchase the original drug through formal channels. For patients who urgently need drugs, they usually have to rely on overseas channels to obtain drugs. The original version is mainly Anamorelin produced in Japan. The common dosage is 50 mg per tablet. Each bottle usually contains 100 tablets, which is suitable for long-term oral use. Anamorelin on the Japanese market has been launched under strict drug supervision and clinical regulations, and its quality and safety have been fully verified.

In addition to the original drug, some overseas countries such as Laos also produce generic versions of anamorelin, which are mainly provided by manufacturers such as Lucius Pharmaceuticals. This type of generic drug is basically the same as the original version in terms of drug ingredients. After passing bioequivalence verification, it can be used clinically as a substitute for the original version, and at the same time, the price is more competitive. Despite this, there are still certain legal, logistical and regulatory risks involved in purchasing drugs overseas. Patients should purchase through legal channels and use them under the guidance of doctors to ensure efficacy and safety.

If domestic patients want to use anamorelin, they usually need to obtain it through cross-border medical treatment, international pharmacies or overseas clinical trial channels, while strictly abiding by drug storage conditions. Since Anamorelin is a prescription drug, the patient's weight, appetite loss, and potential comorbid symptoms need to be assessed before use to avoid safety risks caused by self-administration. As the global demand for cachexia management increases and more clinical data are released, the possibility of Anamorelin being launched in China in the future is gradually increasing, providing patients with greater accessibility.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/